[55], showed that rats, orally receiving radiolabeled LC, metabolized it to -butyrobetaine (up to 31% of the administered dose, present primary in feces) and TMAO (up to 23% of the administered dose, present primary in urine)
At present, immunosuppressants, such as mycophenolate mofetil, azathioprine, and cyclophosphamide, combined with glucocorticoids are commonly used first-line therapy for LN patients
Fat Cell Breakdown: Active ingredients disrupt fat cell membranes
Recently, it was reported that higher phosphatidylcholine intake is linked to an increased risk of fatal cardiovascular disease in US residents, especially in patients with diabetes independent of traditional risk factors
2 x 85 g 3-4 kg ca